BioSpace News Archive

AACC 2019 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest instruments, assays and software for improving speed, accuracy and usability across clinical and research labs during the 71st American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2019).

ZYUS Life Sciences Inc. (“ZYUS”) announced today that it has completed the previously announced acquisition of Kentucky-based healthcare technology company Revon Systems, Inc. (“Revon”).

Gilead Sciences Canada, Inc. (Gilead Canada) today announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults.

AVROBIO, Inc., a Phase 2 clinical-stage gene therapy company, announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City.

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present at the 2019 Wedbush PacGrow Healthcare Conference

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 first fiscal quarter financial results after the close of U.S. financial markets on Tuesday, August 13, 2019.

HemoShear Therapeutics, LLC, a privately held biotechnology company focused on discovering and developing drugs for metabolic disorders, today announced that Jim Powers, Chairman and CEO, will present at the 2019 Wedbush PacGrow Healthcare Conference

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies

Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban

$13.5M revenues, 57% Q2 YOY revenue growth and 520 bps of gross margin increase